Developer docs
API playgroundTry for free, no card

Search company profiles

Nusano

Full company profile

uuid000069i

Namestring
Nusano
Legal namestring
Nusano, Inc.
Websiteurl
nusano.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Nusano is a privately held physics company commercializing a patented ion source and linear accelerator platform for the production of medical and industrial radioisotopes. Its flagship 190,000-square-foot facility in West Valley City, Utah — ribbon-cut in August 2025 — uses custom-built klystrons and fast-pulse modulators to direct a 36 mA alpha/deuteron beam into up to 12 simultaneous target stations, enabling production of 40+ different radioisotopes (including actinium-225, lutetium-177, copper-67, copper-64, astatine-211, iodine-125) at volumes reported as 288-720x greater than existing alpha ion beams and 15-30x the production power of legacy cyclotrons. The company serves pharmaceutical companies developing radiopharmaceutical cancer therapies, hospitals and clinics, advanced nuclear reactor operators (HALEU fuel), aerospace/defense (nuclear batteries), and critical minerals processors, with multi-year supply agreements signed with Clarity Pharmaceuticals, Ariceum Therapeutics, Ratio Therapeutics, Cellectar Biosciences, and dGenThera.

Nusano generates revenue primarily through quote-based B2B supply agreements with drug developers for CGMP-grade radioisotopes, with additional revenue streams planned from HALEU fuel (commercial deliveries beginning Q1 2027), nuclear battery isotopes, and proprietary critical minerals separation services. Distribution is direct enterprise sales, anchored by the Wasatch Group's Lake Park Medical Innovation Campus where Ratio Therapeutics and other partners are co-locating manufacturing to streamline logistics. Co-founders Howard Lewin (Chief Product Development Officer) and Glenn Rosenthal (Chief Technology Officer) lead engineering, while CEO Chris Lowe — a former CFO/COO of Cortexyme with 30 years of healthcare and finance experience — sets commercial direction. The company raised a $115 million Series C in October 2024 led by Wasatch Group with participation from S32 to fund facility ramp.

The company's expansion extends beyond radiopharmaceuticals into adjacent verticals where the same ion source and separation technology applies: HALEU nuclear fuel production (up to 350 metric tons annual capacity targeted), nuclear battery isotopes for space and defense, and critical minerals processing (antimony, cesium, gallium, germanium, rubidium, rare earths) via a Quantum Critical Metals collaboration. A Strategic Advisory Board including former VA Secretary Dr. David J. Shulkin was formed in 2025 to support federal procurement and policy engagement, and CEO Chris Lowe joined the BioUtah Board in November 2025. The company has received the 2025 BioUtah Innovation Impact Award and Utah Business "Best Companies to Work For" recognition.

Short descriptiontext

Nusano is a privately held physics company that uses a patented ion source and 70-foot linear accelerator to produce 40+ medical and industrial radioisotopes, supplying pharmaceutical companies developing cancer radiopharmaceuticals, advanced nuclear reactor operators, and critical minerals processors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWest Valley City, United States
HQ citystring
West Valley City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical radioisotope production, radiopharmaceutical isotope supply, HALEU nuclear fuel, linear accelerator particle technology, critical minerals separation
Industry5 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKACAH
HALEU Production & Supply Chain (Feedstock, Enrichment, Downblending)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Fuel Cycle (Mining, Conversion, Enrichment & Fuel Fabrication)
SECONDARYEUAKAIAB
Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Chemical Manufacturing325
SIC code3 codes
  • Chemicals & Allied Products2800
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Miscellaneous Chemical Products2890
Product category
Medical Radioisotope Production
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Radioisotope Sales
TypeOne Time License
Description

Nusano supplies medical radioisotopes to pharmaceutical companies, hospitals, and clinics for use in cancer diagnostics and therapeutics. Revenue generated through supply agreements with drug developers for isotopes including copper-67, actinium-225, lutetium-177, iodine-125, and astatine-211.

nusano.com
2HALEU Nuclear Fuel
TypeHardware Sales
Description

Production and sale of High-Assay Low-Enriched Uranium (HALEU) for advanced and small modular nuclear reactors. Commercial production deliveries begin Q1 2027, with reservations being accepted.

nusano.com
3Nuclear Battery Isotopes
TypeHardware Sales
Description

Supply of radioisotopes for nuclear batteries used in aerospace, defense, and industrial applications including space satellites and remote sensors

nusano.com
4Critical Minerals Processing
TypeProfessional Services
Description

Proprietary mass separation processes for refining critical minerals including antimony, cesium, gallium, germanium, rubidium, tin, zinc, and rare earth elements

nusano.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nusano operates a patented linear accelerator-based production platform that manufactures 40+ medical, industrial, and energy radioisotopes — including actinium-225, lutetium-177, copper-67, copper-64, astatine-211, and iodine-125 — for sale to pharmaceutical companies, hospitals, and clinics developing cancer diagnostics and radiotherapeutics. The company also produces HALEU nuclear fuel for advanced/small modular reactors and provides critical minerals separation services, with all production centralized at its 190,000-square-foot Utah facility capable of up to 12 simultaneous isotope production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 15-30x production power vs existing cyclotron technology
+3 more records
Product overview1 text field

Nusano operates as a physics company commercializing multiple platform technologies: a radioisotope production platform (ion source + linear accelerator) as the core offering, complemented by stable isotope enrichment and advanced separation techniques. The company's main product lines span life sciences (medical radioisotopes for cancer diagnostics/therapeutics), clean energy (HALEU nuclear fuel, nuclear fuel cycle solutions, nuclear batteries), and critical minerals processing. The 190,000-square-foot Utah facility houses production capabilities for 40+ radioisotopes with simultaneous manufacturing of up to 12 different isotopes. Nusano's proprietary ion source generates heavy ions at 288-720x greater volumes than existing commercial systems, enabling unprecedented production scale.

Product and service6 records
1Medical Radioisotopes
CategoryMedical Radioisotopes / Life Sciences
Description

CGMP-grade medical radioisotopes for healthcare applications including cancer diagnostics and therapeutics. Includes Actinium-225, Lutetium-177, Copper-67, Copper-64, Astatine-211, Iodine-125, Iodine-131, and Fluorine-18 for radiopharmaceutical development. Sold to pharmaceutical companies, hospitals, and clinics.

2HALEU (High-Assay Low-Enriched Uranium)
CategoryClean Energy / Nuclear Fuel
Description

Nuclear fuel for advanced and small modular reactors (SMRs). Nusano's enrichment platform is 200x more efficient than traditional methods, producing 50+ metric tons annually per system with total planned capacity of 350 metric tons through U.S.-based supply chain. Reservations now being accepted with commercial deliveries beginning Q1 2027.

3Nuclear Batteries
CategoryClean Energy / Aerospace & Defense Power
Description

Long-lasting atomic batteries that generate electricity using energy from radioactive decay. Nusano's production platform produces radioisotopes suitable for nuclear batteries, including alpha-emitters with multi-year battery lifespans and low-penetration radiation for compact, durable designs for aerospace, defense, and industrial applications.

4Nuclear Fuel Cycle Solutions
CategoryClean Energy / Nuclear Waste Solutions
Description

Proprietary ion source technology applied to nuclear waste that dramatically shortens the radioactive half-life of spent nuclear fuel while generating clean energy for operation and the electrical grid. Generates neutrons at scale far greater than current particle accelerator technologies.

5Critical Minerals Solutions
CategoryCritical Minerals / Industrial Processing
Description

Proprietary mass separation processes for refining critical minerals including antimony, cesium, gallium, germanium, rubidium, tin, zinc, and rare earth elements. Modular, scalable, and environmentally responsible system that eliminates multiple slow, hazardous, and inefficient steps from conventional ore processing. Offered to mining and processing companies requiring advanced separation technologies.

6Stable Isotope Program
CategoryStable Isotopes / Life Sciences & Industrial
Description

Supply of stable (non-radioactive) isotopes as critical starting materials for radioisotope production. Provides domestic supply security and independence, shortens development time, and expands product lines available for commercialization. Includes enrichment of Gadolinium-160 to 99.2% purity.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-30
Description

Wasatch Group is developing Lake Park Medical Innovation Campus in West Valley City, Utah, with Nusano as anchor tenant. Nusano collaborating with companies throughout the park to advance radiopharmaceutical development and patient care. Joint presence at SNMMI 2026 Annual Meeting.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-07
Description

Non-binding MoU for long-term supply of high-purity lithium chloride from Anson's Green River Lithium Project in Utah. Target of 300 tonnes per annum LCE-equivalent with potential 5-year extension. Nusano will use lithium chloride to produce lithium-6 and lithium-7 isotopes for nuclear sector applications. Sample testing to validate processing capabilities underway.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

MOU for collaboration on critical minerals refining in North America. Quantum to supply material from Canadian projects for refining at Nusano's Utah facility. Target elements include antimony, cesium, gallium, germanium, rubidium, tin, zinc, and rare earth elements. Evaluating joint development of dedicated refining hub in Utah.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Three-year copper-67 supply agreement with automatic renewal. Secures U.S.-based source for copper-67 therapeutic isotope for Clarity's Phase III clinical trial of 67Cu-SAR-bisPSMA for prostate cancer. Supply expected to commence mid-2026. Expands Clarity's network of U.S.-based suppliers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Multi-isotope supply agreement providing actinium-225 (Ac-225) and lutetium-177 (Lu-177) to support Ariceum's radiotherapeutic pipeline. Supports Phase 1/2 SANTANA-225 trial for extensive-stage small cell lung cancer and Merkel cell carcinoma.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Multi-year supply agreement for iodine-125 (I-125) and actinium-225 (Ac-225) supporting clinical studies. Includes CLR 125 for triple-negative breast cancer and CLR 225 for pancreatic cancer. Nusano to produce isotopes at next-generation radioisotope production facility in Utah.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-19
Description

Letter of intent for astatine-211 (At-211) supply for preclinical studies, first-in-human trials, and clinical development of targeted alpha therapies. Quantities sufficient to support dGenThera's proprietary pipeline of theranostic molecular pairs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Long-term multi-isotope supply agreement providing copper-64 for PET imaging diagnostics, lutetium-177 and actinium-225 for therapeutic applications. Supports Ratio's radiopharmaceutical clinical programs including FAP-targeted radiotherapy for soft tissue sarcoma. Ratio's manufacturing facility in Utah will be located near Nusano's operations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NorthStar produces non-uranium based Mo-99 and is expanding into Cu-67, Cu-64, and other therapeutic isotopes. It competes head-to-head with Nusano for U.S. domestic radiopharma supply agreements.

TypeBroad incumbent
Description

Curium is one of the largest global nuclear medicine manufacturers, producing Mo-99, I-131, Lu-177, and other isotopes at multiple facilities. It is an established incumbent Nusano must displace in pharma supply contracts.

TypeDirect peer
Description

SHINE operates a commercial-scale medical isotope production platform (fusion-based) supplying Mo-99, I-131, and Lu-177 to radiopharmaceutical developers. It is the most direct technology-and-business-model analog to Nusano's medical isotope supply strategy.

TypeDirect peer
Description

ITM produces high-purity Lu-177 and other therapeutic radioisotopes and supplies pharma developers globally. It competes with Nusano on Lu-177 specifically and offers an integrated CDMO-plus-isotope model.

TypeBroad incumbent
Description

Lantheus is a vertically integrated radiopharmaceutical company that both develops and manufactures drugs and procures isotopes. Its supplier relationships and internal manufacturing roadmap make it both a potential customer and competitor to Nusano.

TypeBroad incumbent
Description

Telix develops and commercializes radiopharmaceuticals (e.g., Illuccix for prostate imaging) and procures isotopes including Lu-177. It represents the kind of large radiopharma end-market Nusano supplies and may vertically integrate against.

TypeDirect peer
Description

Centrus is the leading U.S. HALEU producer for advanced reactors and is a direct competitor to Nusano's HALEU program, with established DOE relationships and existing commercial cascade operations.

TypeBroad incumbent
Description

BWXT manufactures nuclear components and produces medical isotopes (Mo-99) for the U.S. market. Its established NRC-licensed operations make it a relevant incumbent peer across both medical isotope and adjacent nuclear businesses.

TypeEmerging player
Description

TerraPower is developing advanced reactors (Natrium) that require HALEU fuel, making it a logical downstream customer for Nusano's HALEU output. Comparable as a next-gen nuclear platform beneficiary.

TypeBroad incumbent
Description

Westinghouse is a major nuclear fuel and reactor vendor expanding into SMR (eVinci) and HALEU-adjacent offerings. It is a broader incumbent competing for the same advanced-reactor fuel supply chain.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nusano

Medical Radioisotope Productionnusano.com

Nusano is a privately held physics company that uses a patented ion source and 70-foot linear accelerator to produce 40+ medical and industrial radioisotopes, supplying pharmaceutical companies developing cancer radiopharmaceuticals, advanced nuclear reactor operators, and critical minerals processors.

What Nusano does

Nusano is a privately held physics company commercializing a patented ion source and linear accelerator platform for the production of medical and industrial radioisotopes. Its flagship 190,000-square-foot facility in West Valley City, Utah — ribbon-cut in August 2025 — uses custom-built klystrons and fast-pulse modulators to direct a 36 mA alpha/deuteron beam into up to 12 simultaneous target stations, enabling production of 40+ different radioisotopes (including actinium-225, lutetium-177, copper-67, copper-64, astatine-211, iodine-125) at volumes reported as 288-720x greater than existing alpha ion beams and 15-30x the production power of legacy cyclotrons. The company serves pharmaceutical companies developing radiopharmaceutical cancer therapies, hospitals and clinics, advanced nuclear reactor operators (HALEU fuel), aerospace/defense (nuclear batteries), and critical minerals processors, with multi-year supply agreements signed with Clarity Pharmaceuticals, Ariceum Therapeutics, Ratio Therapeutics, Cellectar Biosciences, and dGenThera.

Nusano generates revenue primarily through quote-based B2B supply agreements with drug developers for CGMP-grade radioisotopes, with additional revenue streams planned from HALEU fuel (commercial deliveries beginning Q1 2027), nuclear battery isotopes, and proprietary critical minerals separation services. Distribution is direct enterprise sales, anchored by the Wasatch Group's Lake Park Medical Innovation Campus where Ratio Therapeutics and other partners are co-locating manufacturing to streamline logistics. Co-founders Howard Lewin (Chief Product Development Officer) and Glenn Rosenthal (Chief Technology Officer) lead engineering, while CEO Chris Lowe — a former CFO/COO of Cortexyme with 30 years of healthcare and finance experience — sets commercial direction. The company raised a $115 million Series C in October 2024 led by Wasatch Group with participation from S32 to fund facility ramp.

The company's expansion extends beyond radiopharmaceuticals into adjacent verticals where the same ion source and separation technology applies: HALEU nuclear fuel production (up to 350 metric tons annual capacity targeted), nuclear battery isotopes for space and defense, and critical minerals processing (antimony, cesium, gallium, germanium, rubidium, rare earths) via a Quantum Critical Metals collaboration. A Strategic Advisory Board including former VA Secretary Dr. David J. Shulkin was formed in 2025 to support federal procurement and policy engagement, and CEO Chris Lowe joined the BioUtah Board in November 2025. The company has received the 2025 BioUtah Innovation Impact Award and Utah Business "Best Companies to Work For" recognition.

Nusano firmographics

Firmographics
Name
Nusano
Legal name
Nusano, Inc.
Website
https://nusano.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Nusano is a privately held physics company that uses a patented ion source and 70-foot linear accelerator to produce 40+ medical and industrial radioisotopes, supplying pharmaceutical companies developing cancer radiopharmaceuticals, advanced nuclear reactor operators, and critical minerals processors.
Ownership category
akta.pro rank

Nusano industry classification

Industry
Product category
Medical Radioisotope Production
NAICS
Irradiation Apparatus Manufacturing (334517), Chemical Manufacturing (325)
SIC
Chemicals & Allied Products (2800), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKACAH
HALEU Production & Supply Chain (Feedstock, Enrichment, Downblending)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Fuel Cycle (Mining, Conversion, Enrichment & Fuel Fabrication)
SECONDARYEUAKAIAB
Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Medical radioisotope production
  • Radiopharmaceutical isotope supply
  • HALEU nuclear fuel
  • Linear accelerator particle technology
  • Critical minerals separation

Where Nusano is headquartered

Location

Headquarters

HQ city
West Valley City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nusano business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Infrastructure, Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Radioisotope Sales: Nusano supplies medical radioisotopes to pharmaceutical companies, hospitals, and clinics for use in cancer diagnostics and therapeutics. Revenue generated through supply agreements with drug developers for isotopes including copper-67, actinium-225, lutetium-177, iodine-125, and astatine-211.
  2. HALEU Nuclear Fuel: Production and sale of High-Assay Low-Enriched Uranium (HALEU) for advanced and small modular nuclear reactors. Commercial production deliveries begin Q1 2027, with reservations being accepted.
  3. Nuclear Battery Isotopes: Supply of radioisotopes for nuclear batteries used in aerospace, defense, and industrial applications including space satellites and remote sensors
  4. Critical Minerals Processing: Proprietary mass separation processes for refining critical minerals including antimony, cesium, gallium, germanium, rubidium, tin, zinc, and rare earth elements

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Nusano product offering

Product offering

Core offering

Nusano operates a patented linear accelerator-based production platform that manufactures 40+ medical, industrial, and energy radioisotopes — including actinium-225, lutetium-177, copper-67, copper-64, astatine-211, and iodine-125 — for sale to pharmaceutical companies, hospitals, and clinics developing cancer diagnostics and radiotherapeutics. The company also produces HALEU nuclear fuel for advanced/small modular reactors and provides critical minerals separation services, with all production centralized at its 190,000-square-foot Utah facility capable of up to 12 simultaneous isotope production.

Product overview

Nusano operates as a physics company commercializing multiple platform technologies: a radioisotope production platform (ion source + linear accelerator) as the core offering, complemented by stable isotope enrichment and advanced separation techniques. The company's main product lines span life sciences (medical radioisotopes for cancer diagnostics/therapeutics), clean energy (HALEU nuclear fuel, nuclear fuel cycle solutions, nuclear batteries), and critical minerals processing. The 190,000-square-foot Utah facility houses production capabilities for 40+ radioisotopes with simultaneous manufacturing of up to 12 different isotopes. Nusano's proprietary ion source generates heavy ions at 288-720x greater volumes than existing commercial systems, enabling unprecedented production scale.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical Radioisotopes CGMP-grade medical radioisotopes for healthcare applications including cancer diagnostics and therapeutics. Includes Actinium-225, Lutetium-177, Copper-67, Copper-64, Astatine-211, Iodine-125, Iodine-131, and Fluorine-18 for radiopharmaceutical development. Sold to pharmaceutical companies, hospitals, and clinics.
  • HALEU (High-Assay Low-Enriched Uranium) Nuclear fuel for advanced and small modular reactors (SMRs). Nusano's enrichment platform is 200x more efficient than traditional methods, producing 50+ metric tons annually per system with total planned capacity of 350 metric tons through U.S.-based supply chain. Reservations now being accepted with commercial deliveries beginning Q1 2027.
  • Nuclear Batteries Long-lasting atomic batteries that generate electricity using energy from radioactive decay. Nusano's production platform produces radioisotopes suitable for nuclear batteries, including alpha-emitters with multi-year battery lifespans and low-penetration radiation for compact, durable designs for aerospace, defense, and industrial applications.
  • Nuclear Fuel Cycle Solutions Proprietary ion source technology applied to nuclear waste that dramatically shortens the radioactive half-life of spent nuclear fuel while generating clean energy for operation and the electrical grid. Generates neutrons at scale far greater than current particle accelerator technologies.
  • Critical Minerals Solutions Proprietary mass separation processes for refining critical minerals including antimony, cesium, gallium, germanium, rubidium, tin, zinc, and rare earth elements. Modular, scalable, and environmentally responsible system that eliminates multiple slow, hazardous, and inefficient steps from conventional ore processing. Offered to mining and processing companies requiring advanced separation technologies.
  • Stable Isotope Program Supply of stable (non-radioactive) isotopes as critical starting materials for radioisotope production. Provides domestic supply security and independence, shortens development time, and expands product lines available for commercialization. Includes enrichment of Gadolinium-160 to 99.2% purity.

Quantifiable outcome

  • 15-30x production power vs existing cyclotron technology
  • +3 more outcomes

Companies that use Nusano

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles5 records

Nusano technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Nusano partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Wasatch GroupcoreStrategic or Co-development Partner · 30 May 2026Wasatch Group is developing Lake Park Medical Innovation Campus in West Valley City, Utah, with Nusano as anchor tenant. Nusano collaborating with companies throughout the park to advance radiopharmaceutical development and patient care. Joint presence at SNMMI 2026 Annual Meeting.
  • Anson ResourcescoreStrategic or Co-development Partner · 7 December 2025Non-binding MoU for long-term supply of high-purity lithium chloride from Anson's Green River Lithium Project in Utah. Target of 300 tonnes per annum LCE-equivalent with potential 5-year extension. Nusano will use lithium chloride to produce lithium-6 and lithium-7 isotopes for nuclear sector applications. Sample testing to validate processing capabilities underway.
  • Quantum Critical MetalscoreStrategic or Co-development Partner · 24 November 2025MOU for collaboration on critical minerals refining in North America. Quantum to supply material from Canadian projects for refining at Nusano's Utah facility. Target elements include antimony, cesium, gallium, germanium, rubidium, tin, zinc, and rare earth elements. Evaluating joint development of dedicated refining hub in Utah.
  • Clarity PharmaceuticalscoreStrategic or Co-development Partner · 16 October 2025Three-year copper-67 supply agreement with automatic renewal. Secures U.S.-based source for copper-67 therapeutic isotope for Clarity's Phase III clinical trial of 67Cu-SAR-bisPSMA for prostate cancer. Supply expected to commence mid-2026. Expands Clarity's network of U.S.-based suppliers.
  • Ariceum TherapeuticscoreStrategic or Co-development Partner · 14 October 2025Multi-isotope supply agreement providing actinium-225 (Ac-225) and lutetium-177 (Lu-177) to support Ariceum's radiotherapeutic pipeline. Supports Phase 1/2 SANTANA-225 trial for extensive-stage small cell lung cancer and Merkel cell carcinoma.
  • Cellectar BiosciencescoreStrategic or Co-development Partner · 26 June 2025Multi-year supply agreement for iodine-125 (I-125) and actinium-225 (Ac-225) supporting clinical studies. Includes CLR 125 for triple-negative breast cancer and CLR 225 for pancreatic cancer. Nusano to produce isotopes at next-generation radioisotope production facility in Utah.
  • dGenTheracoreStrategic or Co-development Partner · 19 June 2025Letter of intent for astatine-211 (At-211) supply for preclinical studies, first-in-human trials, and clinical development of targeted alpha therapies. Quantities sufficient to support dGenThera's proprietary pipeline of theranostic molecular pairs.
  • Ratio TherapeuticscoreStrategic or Co-development Partner · 17 June 2025Long-term multi-isotope supply agreement providing copper-64 for PET imaging diagnostics, lutetium-177 and actinium-225 for therapeutic applications. Supports Ratio's radiopharmaceutical clinical programs including FAP-targeted radiotherapy for soft tissue sarcoma. Ratio's manufacturing facility in Utah will be located near Nusano's operations.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Nusano competitors and assessment

Company assessment

Direct peers

  • NorthStar Medical Radioisotopes: NorthStar produces non-uranium based Mo-99 and is expanding into Cu-67, Cu-64, and other therapeutic isotopes. It competes head-to-head with Nusano for U.S. domestic radiopharma supply agreements.
  • SHINE Medical Technologies: SHINE operates a commercial-scale medical isotope production platform (fusion-based) supplying Mo-99, I-131, and Lu-177 to radiopharmaceutical developers. It is the most direct technology-and-business-model analog to Nusano's medical isotope supply strategy.
  • ITM Isotope Technologies Munich: ITM produces high-purity Lu-177 and other therapeutic radioisotopes and supplies pharma developers globally. It competes with Nusano on Lu-177 specifically and offers an integrated CDMO-plus-isotope model.
  • Centrus Energy: Centrus is the leading U.S. HALEU producer for advanced reactors and is a direct competitor to Nusano's HALEU program, with established DOE relationships and existing commercial cascade operations.

Broad incumbents

  • Curium Pharma: Curium is one of the largest global nuclear medicine manufacturers, producing Mo-99, I-131, Lu-177, and other isotopes at multiple facilities. It is an established incumbent Nusano must displace in pharma supply contracts.
  • Lantheus Holdings: Lantheus is a vertically integrated radiopharmaceutical company that both develops and manufactures drugs and procures isotopes. Its supplier relationships and internal manufacturing roadmap make it both a potential customer and competitor to Nusano.
  • Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceuticals (e.g., Illuccix for prostate imaging) and procures isotopes including Lu-177. It represents the kind of large radiopharma end-market Nusano supplies and may vertically integrate against.
  • BWX Technologies: BWXT manufactures nuclear components and produces medical isotopes (Mo-99) for the U.S. market. Its established NRC-licensed operations make it a relevant incumbent peer across both medical isotope and adjacent nuclear businesses.
  • Westinghouse Electric Company: Westinghouse is a major nuclear fuel and reactor vendor expanding into SMR (eVinci) and HALEU-adjacent offerings. It is a broader incumbent competing for the same advanced-reactor fuel supply chain.

Emerging players

  • TerraPower: TerraPower is developing advanced reactors (Natrium) that require HALEU fuel, making it a logical downstream customer for Nusano's HALEU output. Comparable as a next-gen nuclear platform beneficiary.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nusano social profiles

Digital presence

Nusano financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nusano leadership team

Management profile

Number of profiles

Profiles7 records

Nusano funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nusano M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nusano

What does Nusano do?

Nusano operates a patented linear accelerator-based production platform that manufactures 40+ medical, industrial, and energy radioisotopes — including actinium-225, lutetium-177, copper-67, copper-64, astatine-211, and iodine-125 — for sale to pharmaceutical companies, hospitals, and clinics developing cancer diagnostics and radiotherapeutics. The company also produces HALEU nuclear fuel for advanced/small modular reactors and provides critical minerals separation services, with all production centralized at its 190,000-square-foot Utah facility capable of up to 12 simultaneous isotope production.

Is Nusano a public or private company?

Nusano is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nusano founded?

Nusano was founded in 2013. It employs 101 to 250 people.

Where is Nusano based?

Nusano is headquartered in West Valley City, United States, in the North America region.

How does Nusano make money?

Four revenue lines are on record. Medical Radioisotope Sales are the primary driver. The others are HALEU Nuclear Fuel, nuclear Battery Isotopes and critical Minerals Processing.

Who are Nusano's main competitors?

Direct peers on record are NorthStar Medical Radioisotopes, SHINE Medical Technologies, ITM Isotope Technologies Munich and Centrus Energy. Broad incumbents are Curium Pharma, Lantheus Holdings, Telix Pharmaceuticals, BWX Technologies and Westinghouse Electric Company. TerraPower is listed as an emerging player.

Does Nusano have an API?

No public API is recorded for Nusano.

What industry is Nusano in?

Nusano's product category is Medical Radioisotope Production. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 334517 and its SIC code is 2800.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNusano and Primo Announce Multi-Isotope Supply AgreementNusano and Primo Biotechnology announced a multi-isotope supply agreement to support radiotheranostic development and targeted cancer therapies. The agreement gives Primo access to isotopes including lutetium-177, actinium-225, indium-111, zirconium-89, and terbium-161, with Nusano's platform capable of producing up to 12 isotopes simultaneously.Interesting EngineeringNew HALEU tech targets 5.9 tons of fuel yearly from 1,200-sq-ft unitNusano was selected for a DOE program to produce 5.9 metric tons of HALEU annually from a 1,200-square-foot unit using metallic uranium. The company expects its first unit operational in 2031, addressing a supply gap as US demand could reach 50 metric tons by 2035.PR NewswireNusano's HALEU Platform Selected for NRIC Nuclear Energy Launch Pad USA ProgramNusano was selected by the DOE and NRIC to develop its direct metallization HALEU production line under the Nuclear Energy Launch Pad Program. The system produces 5.9 metric tons of HALEU per year per unit, with the first unit operational in 2031. The company expects U.S. domestic HALEU demand to reach 50 MTU annually by 2035.MINING.COMUS awards $162M to turn mining waste into critical mineralsThe US Department of Energy has selected nine projects for $162 million in potential funding to recover critical minerals from mine waste and industrial feedstocks, aiming to strengthen domestic supplies for energy, defense, and manufacturing. The initiative targets materials such as scandium, copper, antimony, and rare earth elements through technologies developed by companies including Alcoa, Nusano, and Felix Gold. This effort supports the Trump administration's strategy to reduce reliance on Chinese-dominated supply chains by diversifying sources of strategic commodities.B2B SaaS BlogNusano Revenue 2025: $19.7M ARR (Bootstrapped)Nusano, a physics company specializing in medical radioisotopes, reported $19.7 million in annual recurring revenue for 2025 while maintaining its status as a bootstrapped entity with no external funding. Founded in 2015 and headquartered in Valencia, California, the company has grown its workforce to approximately 185 employees over the decade.UsuHuntsman Students Apply Global Consulting Skills to Economic Development in FranceUtah State University students completed a global consulting project for One Provence Promotion, developing strategies to attract foreign investment in the healthcare sector to southern France. The program involved research into companies such as Airbus Helicopters and IPSEN Biopharma, with outcomes including student internships at firms like Nusano.TechbuzznewsNusano Reaches First Accelerator Commissioning Milestone at West Valley FacilityNusano achieved a key technical milestone at its West Valley City facility by successfully directing particles from its proprietary linear accelerator to a target, validating the front-end systems of its new production platform. This 'Beam on Target' event represents the first of three commissioning phases, with full commercial operation expected by the end of 2026. The company aims to address domestic shortages of medical radioisotopes used in diagnostic imaging and cancer therapies.BioSpaceThe future of radiopharma is being built by nuclear geeks in SLCNusano, a Salt Lake City-based physics company, is completing a 190,000-square-foot radioisotope manufacturing facility expected to come online by the end of the year, which will have 15 to 30 times the production power of existing cyclotron technology and be capable of manufacturing 40 different radioisotopes. The facility addresses a critical supply gap in the radiopharmaceutical industry, where therapies like Novartis' Pluvicto and Lutathera have created demand that existing infrastructure cannot adequately support. Several pharmaceutical companies have already reached out about potentially co-locating near the site to access the expanded supply of starting materials for radioligand therapies.Utah BusinessUtah Business Women to Watch 2026: Nicole Vazquez – Utah BusinessNicole Vazquez, Director of Logistics and Customer Service at Nusano, was named to the Utah Business Women to Watch 2026 list for her leadership in supply chain operations. She is currently focused on successfully shipping Nusano’s first product, which involves delivering life-saving isotopes to the radiopharmaceutical industry. This milestone represents a major organizational achievement as the company builds its foundation from the ground up.StockheadStockTake: Anson advances lithium qualification testing in UtahAnson Resources has sent a high-concentration lithium chloride sample to Nusano for qualification testing in Utah. This step is part of an ongoing offtake Memorandum of Understanding aimed at qualifying the product for potential supply to US manufacturers.